Press "Enter" to skip to content

New patent for Eli Lilly drug REYVOW

0
Copyright © DrugPatentWatch. Originally published at New patent for Eli Lilly drug REYVOW

Annual Drug Patent Expirations for REYVOW
Annual Drug Patent Expirations for REYVOW

Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

REYVOW drug price trends.

This drug has thirty-eight patent family members in thirty countries.

The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Eli Lilly drug REYVOW
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions